Table 1.
Characteristics of 362 patients with resected esophageal cancer. Relationship between clinico-pathological parameters and tumor histology stratified into EAC and ESCC. Abbreviations: EAC: esophageal adenocarcinoma, ESCC: esophageal squamous-cell carcinoma, BMI: Body Mass Index, ASA: ASA-Physical status (American Society of Anaesthesiologists), CRP: preoperative C-reactive protein. Chi2-test was used for categorical variables, and rank-sum-test for continuous variables.
| Characteristic | Overall | EAC | ESCC | p Value |
|---|---|---|---|---|
| Number (percent) | 362 (100%) | 224 (61.9%) | 138 (38.1%) | |
| Age (median; range; years) | 62 (22–88) | 64 (22–88) | 61 (31–82) | 0.004 |
| Gender | 0.003 | |||
| Male | 313 (86.5%) | 203 (90.6%) | 110 (79.7%) | |
| Female | 49 (13.5%) | 21 (9.4%) | 28 (20.3%) | |
| BMI (median; range; kg/m2) | 25.3 (14.9–40.9) | 25.7 (14.9–40.9) | 24.4 (14.8–35.0) | 0.0001 |
| ASA | 0.316 | |||
| 1 | 16 (4.4%) | 10 (4.5%) | 6 (4.3%) | |
| 2 | 147 (40.6%) | 100 (44.6%) | 47 (34.1%) | |
| 3 | 169 (46.7%) | 96 (42.9%) | 73 (52.9%) | |
| 4 | 30 (8.3%) | 18 (8.0%) | 12 (8.7%) | |
| CRP (median; range; mg/L) | 3.2 (0.5–260.5) | 2.9 (0.5–229.0) | 3.55 (0.4–260.5) | 0.4648 |
| Tumor location | 0.001 | |||
| Upper third | 30 (8.3%) | 0 (0.0%) | 30 (21.7%) | |
| Middle third | 83 (22.9%) | 13 (5.8%) | 70 (50.7%) | |
| Lower third/cardia | 249 (68.7%) | 211 (94.2%) | 38 (27.6%) | |
| Tumor differentiation | 0.034 | |||
| G1 | 17 (4.8%) | 15 (6.8%) | 2 (1.5%) | |
| G2 | 162 (45.4%) | 93 (41.9%) | 69 (51.1%) | |
| G3 | 178 (49.8%) | 114 (51.3%) | 64 (47.4%) | |
| N/A | 5 | 2 | 3 | |
| Tumor infiltration | 0.003 | |||
| pT0 | 24 (6.6%) | 10 (4.5%) | 14 (10.1%) | |
| pT1 | 83 (22.9%) | 59 (26.3%) | 24 (17.4%) | |
| pT2 | 79 (21.8%) | 53 (23.7%) | 26 (18.8%) | |
| pT3 | 161 (44.5%) | 98 (43.7%) | 63 (45.7%) | |
| pT4 | 15 (4.2%) | 4 (1.8%) | 11 (8.0%) | |
| Lymph node involvement | 0.143 | |||
| pN0 | 185 (51.1%) | 108 (48.2%) | 77 (55.8%) | |
| pN1 | 106 (29.3%) | 65 (29.0%) | 41 (29.7%) | |
| pN2 | 41 (11.3%) | 27 (12.1%) | 14 (10.1%) | |
| pN3 | 30 (8.3%) | 24 (10.7%) | 6 (4.4%) | |
| Tumor stage | 0.001 | |||
| 0 | 9 (2.5%) | 9 (4.0%) | 0 (0.0%) | |
| I | 88 (24.3%) | 51 (22.8%) | 37 (26.8%) | |
| II | 73 (20.2%) | 26 (11.6%) | 47 (34.0%) | |
| III | 112 (30.9%) | 79 (35.3%) | 33 (23.9%) | |
| IVA | 60 (16.6%) | 49 (21.9%) | 11 (8.0%) | |
| IVB | 20 (5.5%) | 10 (4.4%) | 10 (7.3%) | |
| Resection margin | 0.078 | |||
| R0 | 293 (86.9%) | 186 (89.4%) | 107 (82.9%) | |
| R1 | 39 (11.6%) | 21 (10.1%) | 18 (14.0%) | |
| R2 | 5 (1.5%) | 1 (0.5%) | 4 (3.1%) | |
| N/A | 25 | 16 | 9 | |
| Neo-adjuvant treatment | 0.706 | |||
| Yes | 119 (32.9%) | 72 (32.1%) | 47 (34.1%) | |
| No | 243 (67.1%) | 125 (67.9%) | 91 (65.9%) | |
| Adjuvant treatment | 0.017 | |||
| Yes | 61 (17.3%) | 30 (13.6%) | 31 (23.5%) | |
| No | 292 (87.7%) | 191 (86.4%) | 101 (76.5%) | |
| N/A | 9 | 3 | 6 | |
| Tumor recurrence | 0.005 | |||
| Total number of recurrences | 192 (53%) | 107 (29.6%) | 85 (23.5%) | |
| Loco-regional | 32 (8.8%) | 12 (6.3%) | 20 (10.4%) | 0.002 |
| Distant metastases | 160 (44.2%) | 95 (49.5%) | 65 (33.9%) | 0.438 |